Regulatory & Compliance

In a nation where the cost of life-saving medications can bankrupt families, a staggering statistic emerges: biologic drugs, vital for treating conditions like cancer and rheumatoid arthritis, often cost patients upwards of $50,000 annually, creating a significant barrier to access. This leaves

Navigating the Medicare Payment Crisis in Diagnostic Labs In the complex landscape of U.S. healthcare, a staggering threat looms over diagnostic laboratories as Medicare reimbursement cuts for nearly 800 tests, with reductions as steep as 15%, are set to impact the market, prompting urgent calls

The 340B Drug Pricing Program, launched by the federal government in 1992, was designed with a noble purpose: to help safety-net hospitals and clinics provide affordable care to low-income and uninsured individuals by mandating steep drug discounts from manufacturers. However, over the decades,

As open enrollment for Affordable Care Act (ACA) plans begins, millions of Americans face uncertainty and looming price hikes, with Congress yet to decide on extending critical subsidies. To dive deeper into this pressing issue, I’m speaking with Dr. Emily Harper, a renowned healthcare policy

Imagine receiving a letter from a hospital informing you that your Social Security number, health records, and financial details have been exposed to an unknown third party due to a cyberattack, a terrifying reality now faced by over 77,000 individuals connected to Sturgis Hospital in Michigan.

What happens when a program designed to help the most vulnerable patients becomes a sprawling system that some say fuels higher healthcare costs? The 340B drug discount initiative, created to ensure low-income individuals access affordable medications, now stands at a critical turning point. In a